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ABSTRACT 
Background: Individuals living with HIV/AIDS have a higher risk of cardiovascular complications, including hypertension. 
We, therefore, assess the prevalence of hypertension and its association with Tuberculosis in HIV patients on ART in 
Bagamoyo district eastern Tanzania. 
Methods: This was a cross-sectional study involving HIV-infected individuals on ART, consecutively enrolled from two 
selected care and treatment clinics (CTC), between March and May 2019. Hypertension was defined as systolic blood 
pressure (SBP) ≥ 140 mm Hg, diastolic blood pressure (DBP) ≤ 90 mm Hg or being on-ant hypertensive medication 
regardless of blood pressure measurement on the day of the visit. 
Results: We investigated 328 HIV patients on ART, 64.6% were female, 92.68% on non-protease inhibitors, 0.61% had 
current TB and 14% had a history of Tuberculosis in the past 5 years. The overall prevalence of hypertension in HIV patients 
on ART was 29.3% and it was significant and positively associated with increasing age, obesity, family history of 
hypertension, and, current history of TB. However, having a history of Tuberculosis in the past 5 years was not associated 
with increased odds of having hypertension. 
Conclusion: The prevalence of hypertension in HIV patients on ART was higher and it was associated with traditional risk 
factors and the current history of tuberculosis and but not with a history of Tuberculosis in the past 5 years. Regular 
monitoring of blood pressure is crucial among HIV/AIDS patients attending HIV outpatient clinics. 
Keywords: HIV, Hypertension, ART, CTC, Tuberculosis 
Abbreviations: ART: Anti-Retroviral Therapy; BMI: Body Mass Index; CTC: Care and Treatment Clinic; HIV: Human 
Immunodeficiency Virus; TB: Tuberculosis 
INTRODUCTION 
Effective use of antiretroviral therapy (ART), has greatly 
improved the quality of life and survival of people living 
with HIV/AIDS [1]. However, the incidence rate and 
mortality from cardiovascular risk factors including 
hypertension are reported to be growing up [2-4]. For 
example, in a recent meta-analysis study prevalence of 
hypertension was 34.7% among those on ART compared to 
12.7% in ART naïve individuals [5]. In Tanzania, 
hypertension prevalence of (28.3%) in HIV patients on ART 
has been reported at 28.3% which is higher compared to 
5.3% in HIV ART-naïve and 16.3% in HIV negative 
individuals [6]. 
Hypertension (the leading risk factor of deaths) is a growing 
health problem in individuals living with HIV/AIDS [7,8]. 
However, the contributions of HIV related factors include 
Tuberculosis to hypertension have not been extensively 
investigated in Tanzania. In addition to the traditional risk 
factors, hypertension in HIV patients can be attributed to, 
inflammation,  ART   toxicity   and   immune   response  [9]. 
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Traditional risks include risks such as increasing age, sex 
and increasing Body mass index [10]. However, it’s unclear 
whether traditional risk factors may interact with HIV 
related factors such as Tuberculosis (TB) to increase the risk 
of hypertension. 
Evidence exists that TB may contribute to overall 
cardiovascular risk including hypertension perhaps through 
inflammation and autoimmune processes [11,12]. Although 
TB is the most prevalent and severe co-infection in HIV 
patients [13,14], little is known about its association with 
hypertension in HIV patients, especially in developing 
countries. 
Therefore, we undertook a cross-sectional study to 
investigate the prevalence of hypertension and its association 
with TB in HIV patients on ART adjusting for potential 
confounders. To the best level of our knowledge, this cross-
sectional study is the first of its kind to investigate the 
association between TB and hypertension among HIV 
patients on ART while adjusting for confounders. 
METHODS 
Study design and location 
We conducted a cross-sectional study involving HIV 
patients who were on ART between March and April 2019, 
in Bagamoyo district, eastern Tanzania. The district is 
located in the coastal region with an HIV prevalence rate of 
6.4% [15]. Data were collected from 2 public clinics which 
were purposely selected based on their relatively large size 
and presence of patient’s record database (computer-based 
record system). These clinics provide services to individuals 
living with HIV/AIDS based on national HIV/AIDS 
guidelines [16]. 
The inclusion criteria were being HIV positive, aged above 
18, on ART, who gave consent for participation. Women 
who reported to be pregnant and those on contraceptive pills 
were excluded. The patients were then consecutive enrolled 
until the target sample size of 328 was achieved. 
Blood pressure measurement 
Blood pressure was measured in the right arm, using a 
mercury sphygmomanometer of appropriate size, with 
individual participants sitting in a relaxed position and 
upright position [17], two readings were taken 10 min apart 
and an average of two readings was used. Hypertension was 
defined as systolic blood pressure (SBP) of ≥ 140 mm Hg, 
diastolic blood pressure (DBP) of ≥ 90 mm Hg [17] or 
taking ant-hypertensive medications regardless of blood 
pressure findings. 
Anthropometric measurement 
Body weight (accuracy of 0.1 kg) was measured using Seca 
patients weighing machines with individual participants at 
minimal clothes and wearing no shoes. Body height was 
measured using a stadiometer (accuracy of 0.1 cm) 
participant wearing no shoes. Body mass index (BMI) was 
calculated using the formula: weight in kilogram (kg) 
divided by the square of height in meters (kg/m2). BMI was 
categorized and defined using the WHO protocol as follows, 
underweight <18.5 kg/m2, normal body weight 18.5-24.9 
kg/m2, overweight 25-29.9 kg/m2 and obese ≥ 30 kg/m2 [18]. 
Collection of socio-demographic and HIV related 
information 
The study used a structured questionnaire administered by 
trained health care workers (nurses and doctors) was used to 
gather information with respect to participants’ socio-
demographic, family history of hypertension, current history 
of tuberculosis and history of tuberculosis in the past 5 
years. 
The following information was extracted directly from 
patient record card or computerized patient database system: 
Duration since HIV diagnosed, Recent CD4+ cell count, the 
current class of ART medication, individual combination 
therapy and duration on ART medication. 
Definition of terms 
Recent CD4+ cell count was defined as the amount of CD4+ 
T cell count which was measured in the past 6 months. 
Current TB was defined as currently being on anti-TB 
medication after sputum analysis or chest radiography. 
History of TB in the past 5 years was defined as being on 
anti-TB medication for at least 6 months within the last 5 
years. 
Study variables 
The outcome variable of interest was hypertension defined 
as blood pressure ≥ 140/90 mm Hg or being on ant-
hypertensive medication. Exposure variables of interest 
during the analysis were current TB/HIV co-infection and 
the history of TB in the past 5 years. 
Data management and analysis 
Data was collected using a study questionnaire, then coded 
using a codebook followed by the manual entrance in an 
excel sheet. Before data entry in the excel sheet completed 
questionnaire was reviewed for completeness and clarity. 
Before data analysis, another review was done for errors, 
missing data, and inconsistencies. The analysis was done 
using Stata software version 13. 
We included 328 participants in the final analysis and 33 
participants had missing data regarding the recent CD4+cell 
count. Recent CD4+ cell count was defined as the one which 
was taken within the last 6 months. In 33 participants with 
missed data on CD4+ cell count, they had CD4+ cell count 
either not taken at all or taken in a period of more than 6. A 
descriptive analysis (percentage) was used to summarize the 
data. Logistic regression, both univariate and multivariate 
analysis was performed to establish the risk factors of 
hypertension. In the multivariate analysis, we included 
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factors with p-value ≤ 0.005, age, sex and the current class 
of ART. 
ETHICAL APPROVAL 
The study was approved by institutional review of the 
Ifakara Health Institute, Bagamoyo district executive 
director office as well as the authority of the respective 
health facility. Written informed consent was obtained from 
all study participants prior to study procedures. 
RESULTS 
Table 1 summarizes the socio-demographic and TB 
characteristics of the participants. We included 328 HIV 
infected individuals who were on ART for the analysis. Out 
of all participants, 212 (64.6%) were female and 116 
(35.4%) male. In the description of the age categories, 132 
(40.24%), 151 (46.06%) and 45 (13.72%) were individuals 
aged 18-39, 40-59 and ≥ 60, respectively. Out of 328, 89 
(25%) of the participants were either obese or overweight. 
Current alcohol drunker and smoking cigarettes were 
observed in 42 (12.8%) and 17 (5.18%), respectively. 
Out of 328, 2 (0.61%) patients had HIV/TB co-infected and 
46 (14%) of patients had a history of TB in the past 5 years 
(Table 1). There were 304 (92.68%) patients on non-
protease inhibitors and 24 (7.32%) on protease inhibitors, 
with the majority of patients 285(86.89%) were on 
Tenofovir-based combination therapy and the rest were 
either on Zidovudine based combination therapy or 
Atazanivir (Table 1). Data on CD4+ cell count in the last 6 
months was available in 25 (8.47%), 75 (25.42%), 75 
(25.42%) and 120 (40.68%) patients had CD4+ cell count, 
<100, 100-349, 350-499 and ≥ 500, respectively (Table 1). 
Table 1. Socio-demographic and clinical profile of the participants. 
Factors of interesta N (%) 
Overall 328 
Age (Years) 
18-39 132 (40.24) 
40-59 151 (46.06) 
≥ 60 45 (13.72) 
Sex 
Female 212 (64.63) 
Male 116 (35.37) 
Occupation 
Peasant 213 (64.94) 
Others 115 (35.06) 
Current social behavior 
Alcohol drunker 42 (12.80) 
 Smoking cigarette 17 (5.18) 
BMI (kg/m2) 
Underweight (<18.5) 46 (14.02) 
Normal weight (18.5-24.9) 193 (58.84) 
Overweight (25-29.9) 51 (15.55) 
Obese (≥ 30) 38 (11.59) 
Recent CD4 +cell count(cell/µl)b 
 <100 25 (8.47) 
100-349 75 (25.42) 
350-449 75 (25.42) 
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 ≥ 500 120 (40.68) 
Current class of ART 
Protease inhibitors  24 (7.32) 
Non-protease inhibitors 304 (92.68) 
Individual cART 
Zidovudine 19 (5.79) 
Tenofovir 285 (86.89) 
Atazanavir 24 (7.32) 
History of chronic disease 
Family history of hypertension 41 (12.50) 
Current TB/HIV co-infections 2 (0.61) 
History of TB in past 5 years 46 (14.02) 
ART: antiretroviral therapy; BMI: Body Mass Index; cART: Combination Antiretroviral Therapy; CD4: Cluster of 
Differentiation 4; HIV: Human Immune Deficiency Virus; TB: Tuberculosis 
afactors are expressed as a percentage 
b33 missing data for this variable 
In our current study, the overall prevalence of hypertension 
in HIV patients on ART was 96 (29.3%). According to 
gender, the prevalence was 33 (28.5%) in males and 63 
(29.7%) in females (Table 2). Regarding TB infection, the 
prevalence of hypertension was 1 (50%) in those with 
current TB/HIV and 15 (32.6%) in those with a history of 
TB in the past 5 years (Table 2). 
Table 2. Socio-demographic and clinical characteristics associated with hypertension in HIV patients. 
Factors of interesta Hypertensiveb N (%) Non- hypertensive N (%) TOTAL 
Overall 96 (29.3) 232 (70.7) 328 
Age (Years) 
18-39 22 (16.7) 111 (83.3) 132 
40-59 50 (33.1) 101 (66.9) 151 
≥ 60 24 (53.3) 21 (46.7) 45 
Sex 
Female 63 (29.7) 149 (70.3) 212 
Male 33 (28.5) 83 (71.6) 116 
Occupation 
Peasants 63 (29.6) 150 (70.4) 213 
Others 33 (28.7) 82 (71.3) 115 
Current social behavior 
Alcohol drunker 13 (39.1) 29 (69.1) 42 
Smoking cigarette 7 (41.2) 10 (58.8) 17 
BMI (kg/m2) 
Underweight (<18.5) 2 (4.4) 44 (95.6) 46 
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Normal weight (18.5-24.9) 53 (27.5) 140 (72.5) 193 
Overweight (25-29.9) 20 (39.2) 31 (61.8) 51 
Obese (≥ 30) 21 (55.3) 17 (44.7) 38 
Recent CD4+ cell count(cell/µl) 
<100 7 (28) 18 (72) 25 
100-349 23 (30.7) 52 (69.3) 75 
350-449 22 (29.3) 53 (70.7) 75 
≥ 500 36 (30.0) 84 (70.0) 120 
Current group of ART 
Protease inhibitors 3 (12.5) 21 (87.5) 24 
Non-protease inhibitors 93 (30.6) 211 (69.4) 304 
Individual cART 
Zidovudine 8 (42.1) 11 (57.9) 19 
Tenofovir 85 (29.4) 204 (70.6) 289 
Atanazavir 3 (15) 17 (85) 20 
History of chronic disease 
Family history of hypertension 20 (48.8) 21 (51.2) 41 
Current TB/HIV co-infections 1 (50.0) 1 (50.0) 2 
History of TB in past 5 years 15 (32.6) 31 (67.4) 46 
ART: Antiretroviral Therapy; BMI: Body Mass Index; cART: Combination Antiretroviral Therapy; CD4: Cluster of 
Differentiation 4; HIV: Human Immune Deficiency Virus; TB: Tuberculosis 
afactors are expressed as percentage 
bhypertensive defined as systolic BP ≥ 140, diastolic BP ≥ 90 after an average of two readings taken at least 10 min and 
current use of hypertensive medications regardless of BP findings 
c33 missing data  for this variable 
In univariate logistic regression analysis, the factors that 
were significantly associated with increased odds of having 
hypertension were: increasing age, higher BMI, family 
history of hypertension and non-protease inhibitors (Table 
3). The odds for hypertension were highest among 
individuals ≥ 60 years of age, odds ratio 5.71 (2.72-12.01) 
<0.001 and those 40-59 years of age had an odds ratio of 
2.48 (1.40-4.37) <0.001 (Table 3). Moreover, regarding 
body mass index obese hold the highest odds ratio of 3.3 
(1.60-6.66) <0.001 and overweight 1.70 (0.89-3.25) <0.001 
(Table 3). A family history of hypertension and non-
protease inhibitors had an odds ratio of 2.64 (1.36-5.15) 
<0.001 and 3.09 (0.89-10.6) <0.001, respectively (Table 3). 
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Table 3. Univariate analysis of factors associated with hypertension (N=328). 
Factor of interest n Odds ratios (95% CI) P value 
Age (years) 
18-39 132 1 
<0.001 40-59 151 2.48 (1.40-4.37) 
≥ 60 45 5.71 (2.72-12.01) 
Sex 
Male 116 1 
0.810 
Female 212 1.06 (0.65-1.78) 
Occupation status 
Peasant 213 1 
0.867 
Non peasant 115 0.96 (0.58-1.58) 
Current social behavior 
Alcohol drunker 
0.80 No 286 
Yes 42 1.10 (0.54-2.21) 
Smoking cigarette 
0.282 No 311 1 
Yes 17 1.75 (0.64-4.73) 
BMI (kg/m2) 
Normal weight (18.5-24.9) 193 1 
<0.001 
Underweight (<18.5) 46 0.12 (0.28-0.51) 
Overweight (25-29.9) 51 1.70 (0.89-3.25) 
Obese (≥ 30) 38 3.3 (1.6-6.66) 
Recent CD4+ cell count (cell/µl) d 
<100 25 1 
0.995 
100-349 75 1.13 (0.42-3.09) 
350-499 75 1.07 (0.39-2.91) 
≥ 500 120 1.10 (0.42-2.87) 
Current group of ARV medications 
Protease inhibitors 24 1 
0.043 
Non- protease inhibitors 304 3.09 (0.89-10.6) 
Individual cART 
Zidovudine 19 5.09 (1.12-23.14) 
0.0712 
Tenofovir 289 2.98 (0.86-10.24) 
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Atazanavir 20 Omitted 
History of chronic diseases 
Family history of hypertension 
005 No 41 1 
Yes 287 2.64 (1.36-5.15) 
Current TB/HIV co-infections 
0.538 No 326 1 
Yes 2 2.42 (0.15-39.28) 
History of TB in past 5 years 
0.595 No 282 1 
Yes 46 1.2 (0.62-2.34) 
ART: Antiretroviral Therapy; BMI: Body Mass Index; cART: Combination Antiretroviral Therapy; CD4: Cluster of 
Differentiation 4; HIV: Human Immune Deficiency Virus; TB: Tuberculosis 
b=hypertensive defined as systolic BP ≥ 140, diastolic BP ≥ 90 after an average of two readings taken at least 10 min and 
current use of hypertensive medications regardless of BP findings 
d=33 missing data 
In the multivariate analysis, HIV related factors that were 
independently associated with increased odds of having 
hypertension were, non-protease inhibitors 4.31 (1.16-16.03) 
<0.001, current TB/HIV co-infection 3.13 (0.12-80.41) 
<0.001, Zidovudine 4.66 (0.91-23.99) <0.001 and tenofovir 
4.27 (1.15-15.96) <0.001. However, recent CD4+ count and 
history of TB in the past 5 years were not associated with 
increased odds of hypertension (Table 4). 
Table 4. Multivariate analysis of factors associated with hypertension (N=328). 
Factor of interest n Adjusted odds ratios (95% CI) P value 
Age (years) 
18-39 132 1 
<0.001 40-59 151 3.40 (1.80-6.41) 
≥ 60 45 9.25 (3.96-21.60) 
Sex 
Male 116 1 
<0.001 
Female 212 0.78 (0.43-1.40) 
Occupation status 
Peasant 213 1 
<0.001 
Non peasant 115 1.24 (0.69-2.24) 
Current social behavior 
Alcohol drunker 
<0.001 No 286 1 
Yes 42 1.29 (0.57-2.92) 
Smoking cigarette 
<0.001 
No 311 1 
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Yes 17 2.12 (0.65-6.90) 
BMI (kg/m2) 
Normal weight (18.5-24.9) 193 1 
<0.001 
Underweight (<18.5) 46 0.70 (0.02-0.32) 
Overweight (25-29.9) 51 1.61 (0.77-3.36) 
Obese (≥ 30) 38 3.63 (1.60-8.26) 
Recent CD4+ cell count(cell/µl) d 
<100 25 1 
<0.001 
100-349 75 0.90 (0.30-2.70) 
350-499 75 1.04 (0.34-3.16) 
≥ 500 120 1.25 (0.43-3.60) 
Current group of ART 
Protease inhibitors 24 1 
<0.001 
Non-protease inhibitors 304 4.31 (1.16-16.03) 
Individual cART 
Zidovudine 19 4.66(0.91-23.99 
<0.001 Tenofovir 285 4.27(1.15-15.96) 
Atazanavir 24 Omitted 
History of chronic diseases 
Family history of hypertension 
<0.001 No 41 1 
Yes 287 2.73 (1.27-5.84) 
Current TB/HIV co-infections 
<0.001 No 326 1 
Yes 2 3.13 (0.12-80.41) 
History of TB in past 5 years 
<0.001 No 282 1 
Yes 46 1.15 (0.55-2.43) 
ART: Antiretroviral Therapy; BMI: Body Mass Index; cART: Combination Antiretroviral Therapy; CD4: Cluster of 
Differentiation 4; HIV: Human Immune Deficiency Virus; TB: Tuberculosis 
b=hypertensive defined as  systolic BP ≥ 140, diastolic BP ≥ 90 after an average of two readings taken at least 10 min and 
current use of hypertensive medications regardless of BP findings 
d=33 missing data 
DISCUSSION 
In this cross-sectional study analyzing the prevalence of 
hypertension and its association with TB among HIV 
patients, we found the prevalence of hypertension to be 
29.3%. We also observed that the odds of having 
hypertension were significantly associated with increasing 
age, obesity, and family history of hypertension and non-
protease inhibitors. Current TB/HIV co-infection was found 
to increase the odds of having hypertension in multivariate 
analysis. 
SciTech Central Inc. 
Int J AIDS (IJA) 70 
Int J AIDS, 1(2): 62-71     Nyangi GI, Festo C & Olotu A 
The high prevalence (29.3%) in our current study appears 
similar to that of the observed prevalence in previous studies 
in HIV patients [5,6]. This strengthens the evidence that the 
prevalence of hypertension is higher in HIV patients on 
ART. 
We also observed factors that were significant and positively 
associated with increased odds of hypertension which 
included: increasing age, obesity and family history of 
hypertension. These findings are consistent with previous 
studies [19,20]. This supports the evidence that traditional 
risk factors are potential predictors of hypertension even in 
HIV patients. 
The interaction between TB infection and hypertension in 
HIV patients has been reported in the literature [11]. The 
possible mechanism by which TB can cause hypertension is 
through the inflammatory process which can end up with 
atherosclerosis [11]. Furthermore, TB can contribute to 
hypertension, because it can lead to diabetes mellitus 
[21] and diabetes mellitus itself is the risk factor of 
hypertension [22]. Additionally, hypertension may occur 
secondarily from renal failure after TB causing 
extensive destruction of kidney parenchyma tissues [23]. 
In our current study, we found that current TB/HIV co-
infection increases the odds of having hypertension 
3.13 (0.12-80.41) <0.001 in multivariate analysis. 
This result differs from the study in Dare Salaam 
Tanzania which found no significant association 
between current TB/HIV co-infection and 
hypertension [24]. However, we cannot justify 
the association between current TB and hypertension based on 
2 patients with current TB infection which is a very 
small number to conclude. Therefore, in our current 
study, the interpretation regarding the association 
between current TB and hypertension in HIV patients 
on ART should be made with caution. 
In our current study, we also found that having a history 
of TB in  the past 5 years did  not increase the odds of 
having  hypertension, contrary to the previous study 
in Dar es Salaam, Tanzania which reported a protective 
effect of prior history of TB against hypertension 
[24]. An important difference to note is that in our 
current study we limited the history of the previous TB to 
within 5 years while the study by Njelekela et al. [24], 
had no time limit concerning the prior history of TB. 
We recommend further studies to investigate more 
about the association between TB and hypertension in 
HIV patients on ART. 
CONCLUSION 
The prevalence of hypertension in HIV patients on ART 
was higher and it was associated with traditional risk 
factors but not with the history of Tuberculosis in the past 
5 years. We cannot justify the association between 
current TB infection and hypertension based on 2 
patients with current TB infection which is a very small 
number to conclude. 
Routine screening of blood pressure and health education, 
body weight control, healthy diet, physical activity should be 
emphasized as essential components of treatment and care of 
HIV patients. We recommend further longitudinal studies to 
explore more on the association between TB and 
hypertension in HIV patients. 
We faced the followings limitations: being cross-sectional 
we cannot establish causality between selected exposure 
variable and outcome variable. Also, we did not include 
HIV-negative individuals to make a comparison between the 
two groups. Again we cannot justify the association between 
current TB infection and hypertension based on 2 patients 
with current TB infection which is a very small number. 
Despite the mentioned limitations, this study provided 
important results regarding the association between TB and 
hypertension in HIV patients on ART, particularly in low-
income countries. 
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